PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition. (Q41994295)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

title

PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Florian Gnad

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

25

Elizabeth M Jaffee

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

26

Lei Zheng

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

author name string

Wei Zhou

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Adrian M Jubb

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Karen Lyle

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Qian Xiao

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Christy C Ong

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Rupal Desai

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Ling Fu

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Qinghua Song

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Peter M Haverty

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Daniela Aust

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Robert Grützmann

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Mally Romero

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Klara Totpal

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Richard M Neve

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Yibing Yan

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

William F Forrest

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Yulei Wang

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Rajiv Raja

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Ana de Jesus-Acosta

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Marcia Belvin

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Lori S Friedman

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Mark Merchant

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Hartmut Koeppen

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Klaus P Hoeflich

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

publication date

6 October 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

volume

234

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

page(s)

502-513

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit

11 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

p21-Activated protein kinases and their emerging roles in glucose homeostasis

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

Pak1 kinase links ErbB2 to β-catenin in transformation of breast epithelial cells

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

5 June 2018

PAK signaling in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

PAK family kinases: Physiological roles and regulation

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

Molecular pathways: targeting p21-activated kinase 1 signaling in cancer--opportunities, challenges, and limitations

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

Targeting MET in cancer: rationale and progress

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

Inhibition or ablation of p21-activated kinase (PAK1) disrupts glucose homeostatic mechanisms in vivo

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

Signalling to cancer cell invasion through PAK family kinases

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

PAK4: a pluripotent kinase that regulates prostate cancer cell adhesion

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

PAK1 and PAK2 have different roles in HGF-induced morphological responses

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

PAK1 interacts with beta-catenin and is required for the regulation of the beta-catenin signalling pathway by gastrins

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

Achaete-scute like 2 (ascl2) is a target of Wnt signalling and is upregulated in intestinal neoplasia

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

Activation of cdc42, rac, PAK, and rho-kinase in response to hepatocyte growth factor differentially regulates epithelial cell colony spreading and dissociation

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

Growth dependency of a new human pancreatic cancer cell line, YAPC, on autocrine interleukin-1alpha stimulation

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

New tools and novel approaches in treating locally advanced pancreatic adenocarcinoma.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

Neural Invasion in the Staging of Pancreatic Cancer

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4380185

Expression of hepatocyte growth factor, keratinocyte growth factor and their receptors in experimental chronic pancreatitis

18 August 2018

1 reference

12 December 2020

Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer

1 reference

12 December 2020

c-Met is a marker of pancreatic cancer stem cells and therapeutic target

1 reference

12 December 2020

Synergistic effect of a granulocyte-macrophage colony-stimulating factor-transduced tumor vaccine and systemic interleukin-2 in the treatment of murine colorectal cancer hepatic metastases

1 reference

12 December 2020

Identifiers

DOI

10.1002/PATH.4412

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

release_udjv6k7l6fb3ta3b7noeb5w2y4

11 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/udjv6k7l6fb3ta3b7noeb5w2y4

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25074413%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference